IDV vehicle
75A50119D00018
MAPP 2019 CONTRACT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $37.5M |
| Current contract value | Not reported |
| Potential contract value / ceiling | $50.1M |
| Start date | Jun 3, 2019 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | May 4, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 23 of 23 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 4, 2026 | P00022 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO REVISE ARTICLE G.7. INDIRECT COST RATE. |
| Apr 22, 2026 | P00021 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO ADD ATTACHMENT 11: TRANSFER GOVERNMENT FURNISH PROPERTY (GFP) FROM HHSO100201900018C TO 75A50122C00076. |
| Jul 30, 2025 | P00020 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO 1. EXTEND CLIN 0003 PERIOD OF PERFORMANCE FROM 30 SEP 2025 TO 30 JUN 2026 AND 2. REVISE PRIMARY AND ALTERNATE COR. 3. TRANSFER GFP |
| Apr 18, 2025 | P00019 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO REVISE ARTICLE G.7. INDIRECT COST RATE |
| Mar 19, 2025 | P00018 | $0 | THE PURPOSE THIS NO COST MODIFICATION IS TO: 1) EXTEND THE PERIOD OF PERFORMANCE FOR CLIN 0003 THROUGH SEPTEMBER 30, 2025 AND 2) ADD ATTACHMENT 09 - EO FAR CLAUSE CHANGES FOR EXISTING CONTRACTS. |
| Jan 21, 2025 | P00017 | $0 | NO COST MODIFICATION TO CHANGE PRIMARY AND SECONDARY COR. |
| Aug 29, 2024 | P00016 | $0 | NO COST MODIFICATION TO REVISE THE STATEMENT OF WORK. |
| Aug 15, 2024 | P00015 | $0 | NO COST MODIFICATION TO REVISE THE PROVISIONAL RATES FOR SECTION G.7 INDIRECT COST RATES. |
| Jul 18, 2024 | P00014 | $0 | UNILATERAL NO COST MODIFICATION TO CORRECT DELIVERY DATE ERRORS WITHIN PRISM, TO ENABLE MAPP BIOPHARMACEUTICAL'S INVOICING IN THE INVOICE PROCESSING PLATFORM (IPP) SYSTEM. |
| Jan 23, 2024 | P00013 | $0 | NO-COST MODIFICATION IS TO TRANSFER GOVERNMENT FURNISHED PROPERTY (GFP) FROM HHSO100201900018C TO 75A50122C00076. |
| Jun 30, 2023 | P00012 | $0 | REVISE INDIRECT RATES AND ADD FAR CLAUSE 52.204-27 |
| Jan 5, 2023 | P00011 | $0 | MAPP BIOPHARMACEUTICAL - TRANSFER GFP TO TO CONTRACT 75A50122C00076. |
| Dec 5, 2022 | P00010 | $720.0K | MAPP BIOPHARMACEUTICAL - SUPPLEMENTAL FUNDING FOR CLIN 0001 INDIRECT RATES. |
| Jul 19, 2022 | P00009 | $0 | MAPP BIOPHARMACEUTICAL - REVISE BASE PERIOD CLIN 00001 IAW MODIFICATION P00005. |
| Apr 7, 2022 | P00008 | $0 | REVISE INDIRECT COST RATES AND INVOICE SUBMISSION INSTRUCTIONS. |
| Feb 24, 2022 | P00007 | $0 | REVISE STATEMENT OF WORK (SOW). |
| Feb 1, 2022 | P00006 | $0 | TRANSFER GOVERNMENT FURNISHED PROPERTY TO HHSO100201600021C AND ADDITIONAL ADMINISTRATIVE REVISIONS. |
| Jan 10, 2022 | P00005 | $7.3M | EXERCISE CLIN 0003 PHASE 1 CLINICAL STUDY |
| Nov 2, 2021 | P00004 | $0 | MODIFY ARTICLE G.7. INDIRECT RATES UPDATE CO ASSIGNMENT |
| Mar 8, 2021 | P00003 | $0 | ADD ALTERNATE COR TO CONTRACT |
| Dec 2, 2020 | P00002 | $13.0M | EXERCISE CLIN 0002, OPTION 1 FOR THE ADVANCED DEVELOPMENT OF AN ANTI-MARBURG VIRUS (MBP091) MEDICAL COUNTERMEASURE |
| Jun 17, 2020 | P00001 | $0 | DEVELOPMENT OF AN ANTI?MARBURG VIRUS (MBP091) MEDICAL COUNTERMEASURE |
| Jun 3, 2019 | 0 | $16.5M | MAPP 2019 CONTRACT |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.